%20(dragged)-1752956736212.webp&w=3840&q=75)
2025 NOSCM | Early Stages Colon Cancer- Use of Biomarkers To Decide Therapy (From MSI to ctDNA)
0% Complete
Course Overview
Dr. Mike Cusnir discussed biomarkers in early-stage colon cancer. MSI-high patients fare better. The ATomic trial showed 80% 3-year survival with immunotherapy + FOLFOX. Neoadjuvant immunotherapy yielded high response rates. MRD testing, ctDNA monitoring, and aspirin for PIK3CA mutations aid treatment.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 20, 2025
- Last Review
- Jul 20, 2025
- Expires
- Jul 20, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Mike Cusnir, MD
Accreditation
NA
